US Patent 9,668,981: Claim Scope, Patent Strength, Expiration and Transdermal Drug-Delivery Landscape

US Patent 9,668,981 protects a transdermal drug-delivery method using an adhesive polymer composition that combines defined soft and hard acrylic monomers, excludes acrylic polymers polymerized with methacrylic acid, and contains 0.3% to 30% drug. The patent becomes materially narrower when the claims require methylphenidate, rubber-based polymers, or silicon-based polymers. Its principal commercial relevance is to transdermal methylphenidate products and other drug-in-adhesive patches using acrylic pressure-sensitive adhesive systems.

The patent is method-of-use and composition-dependent. A competitor that uses a materially different adhesive chemistry, a non-acrylic matrix, methacrylic acid in the acrylic polymer, or a drug concentration outside the claimed ranges may have a noninfringement position. A product-only claim is not present in the claims supplied.

What does US Patent 9,668,981 cover?

The independent claim covers a method of transdermally delivering a drug through administration of a transdermal delivery system containing a polymer composition with two principal elements:

At least one acrylic-based polymer.
One or more drugs at approximately 0.3% to 30% by weight of the composition.

The acrylic polymer must be polymerized from:

A soft acrylic monomer with a glass-transition temperature of approximately -70°C to -10°C, present at 20% to 70% by weight of the acrylic polymer; and
A hard acrylic monomer with a glass-transition temperature of approximately -5°C to 120°C, present at 30% to 80% by weight of the acrylic polymer.

The claim also contains a negative limitation: the acrylic-based polymers are not polymerized with methacrylic acid monomers.

Claim element	Requirement
Claimed activity	Transdermal delivery of a drug
Delivery vehicle	Transdermal drug-delivery system
Core polymer	At least one acrylic-based polymer
Soft monomer	Tg of about -70°C to -10°C
Soft monomer proportion	About 20% to 70% of acrylic-based polymer
Hard monomer	Tg of about -5°C to 120°C
Hard monomer proportion	About 30% to 80% of acrylic-based polymer
Drug loading	About 0.3% to 30% by weight
Exclusion	Acrylic polymer is not polymerized with methacrylic acid
Delivery route	Transdermal

The claim is directed to a polymer matrix or adhesive composition rather than a particular patch geometry, backing layer, release liner, application schedule, or therapeutic indication.

How strong is the independent claim?

Claim 1 has meaningful technical specificity but also several potential vulnerabilities.

Strengths of claim 1

The claim does not merely require an acrylic adhesive. It combines:

A soft/hard acrylic monomer architecture;
Numerical Tg windows for both monomer categories;
Numerical composition ranges for both categories;
A defined drug-loading range; and
An express exclusion of methacrylic acid polymerization.

These limitations can distinguish the claimed formulation from generic acrylic pressure-sensitive adhesives. They also create several formulation variables that may be difficult to avoid while maintaining adhesion, drug solubility, skin compatibility, and controlled delivery.

The negative limitation may be particularly important. A formulation that otherwise satisfies the soft-monomer and hard-monomer requirements may avoid literal infringement if the relevant acrylic polymer is polymerized with methacrylic acid.

Vulnerabilities of claim 1

The claim uses broad functional and compositional language:

“At least one” acrylic-based polymer;
“One or more” drugs;
Broad Tg ranges;
Broad drug-loading ranges; and
“About” before several numerical limits.

The claim also does not identify a single required drug, monomer pair, polymer molecular weight, crosslinker, tackifier, permeation enhancer, backing layer, or release profile. A large number of formulations could therefore fall within the literal scope if the listed numerical limitations are satisfied.

The term “hard acrylic monomer” also requires careful construction. Claim 11 lists “N-butyl acrylate” as a hard acrylic monomer even though butyl acrylate is commonly treated as a soft monomer in adhesive formulation practice. The specification and prosecution history would control how the court reconciles that apparent inconsistency.

What dependent claims add to the patent scope?

Claims 2 through 18 create alternative claim positions. They do not all provide the same commercial value.

Claims	Added limitation	Commercial significance
2	Drug comprises methylphenidate	Directly targets transdermal methylphenidate products
3	Drug loading of about 0.5% to 15%	Narrows drug concentration
4	Drug loading of about 1% to 10%	Further narrows concentration
5	Drug loading of 0.3% to 30%	Restates the broad independent range
6	Soft monomer Tg of about -60°C to -20°C	Narrows soft-monomer window
7	Soft monomer Tg of about -60°C to -24°C	Further narrows soft-monomer window
8	Lists specific soft monomers	Provides formulation-specific coverage
9	Hard monomer Tg of about 10°C to 120°C	Excludes lower hard-monomer Tg values
10	Hard monomer Tg of about 10°C to 105°C	Further narrows hard-monomer window
11	Lists specific hard monomers	Provides formulation-specific coverage
12-15	Adds rubber-based polymer, including polyisobutylene	Covers acrylic/rubber adhesive blends
16-18	Adds silicon-based polymer, including polysiloxane	Covers acrylic/silicone adhesive blends

Methylphenidate coverage

Claim 2 is the most commercially targeted dependent claim. It covers a method in which the drug includes methylphenidate, but it does not require methylphenidate to be the only drug or specify methylphenidate salt, isomer, particle size, dosage, or delivery rate.

A transdermal methylphenidate product would require a limitation-by-limitation analysis of:

The acrylic polymer’s monomer composition;
The Tg values assigned to the monomers;
The relative amount of soft and hard monomers;
The presence or absence of methacrylic acid;
Total drug loading; and
Whether the accused product is administered for transdermal delivery.

Rubber-polymer claims

Claims 12 through 15 cover acrylic compositions that also include rubber-based polymers. Claim 15 specifically identifies polyisobutylene, a widely used pressure-sensitive adhesive component.

These claims can reach a formulation that uses acrylic polymer as one adhesive phase and polyisobutylene as another. They do not require a particular ratio unless claim 13 is asserted. Claim 13 requires:

Acrylic-based polymer: 2% to approximately 95% by weight of the composition; and
Rubber-based polymer: 4% to approximately 97% by weight.

The ranges overlap substantially and may permit many blend ratios. The claim language should be tested against the written description and prosecution history for written-description and enablement issues at the outer ends of the ranges.

Silicon-polymer claims

Claims 16 through 18 address compositions containing a silicon-based polymer, including a polysiloxane polymer. Claim 17 applies the same broad 2% to 95% acrylic and 4% to 97% silicon-polymer ranges found in claim 13.

These claims have potential relevance to hybrid acrylic/silicone adhesive systems. They are less directly aligned with a conventional acrylic-only methylphenidate patch unless the product contains a qualifying silicon-based polymer.

What formulations are protected by US 9,668,981?

The principal protected formulation categories are:

Acrylic-only drug-in-adhesive systems

These systems contain an acrylic polymer formed from soft and hard monomers within the claimed Tg and percentage ranges. The drug may be methylphenidate or another active pharmaceutical ingredient.

Examples of listed soft monomers include:

2-Ethylhexyl acrylate;
Isobutyl acrylate;
Ethyl acrylate;
Butyl acrylate;
Dodecyl methacrylate;
2-Ethylhexyl methacrylate; and
2-Ethoxyethyl acrylate.

Listed hard monomers include:

Acrylic acid;
Butyl methacrylate;
Ethyl methacrylate;
Methyl methacrylate;
Hexyl methacrylate; and
Methyl acrylate.

Acrylic/rubber blends

The claims identify polyisobutylene, polyisoprene, polybutylene, styrene block copolymers, styrene-isoprene-styrene polymers, styrene/butadiene polymers, and related hydrocarbon or halogen-containing polymers.

Acrylic/silicone blends

The patent also covers compositions containing polysiloxane or another silicon-based polymer, subject to the acrylic-polymer and drug-loading limitations inherited from claim 1.

When does US Patent 9,668,981 lose exclusivity?

The patent issued on June 6, 2017. Its expiration depends on the earliest effective nonprovisional filing date, any patent-term adjustment, terminal disclaimer, patent-term extension, and the priority chain.

Public patent records associate the patent family with a priority period beginning in 2009. On that basis, the ordinary 20-year term would be expected to expire in approximately 2029, subject to the official USPTO term calculation. The patent is not a small-molecule regulatory exclusivity right, and the patent term does not automatically extend because the covered drug is approved by the FDA.

Event	Date or status
Earliest family priority	2009 family priority reported in public patent records
Patent issued	June 6, 2017
Ordinary term basis	20 years from applicable earliest nonprovisional filing
Expected ordinary expiration	Approximately 2029
PTE relevance	No drug-specific patent-term extension is established from the claim text
PTA relevance	Must be included if awarded by the USPTO
Terminal disclaimer	Must be checked in the file history

The operative expiration date should be taken from the USPTO Patent Center record rather than calculated solely from the issue date. Patent expiration is particularly important if the patent is asserted against a later generic or reformulated patch.

What is the Orange Book status of US 9,668,981?

The claims are not limited to an FDA-approved product, dosage strength, or indication. They are drafted as broad transdermal delivery-method claims. That structure makes Orange Book listing less straightforward than a patent claiming an approved drug substance, formulation, or approved method of use.

For a methylphenidate transdermal product, the relevant reference product would be Daytrana, marketed by a Noven-related entity and approved under NDA 021514. The Orange Book analysis should distinguish:

Patents listed for the approved NDA;
Patents covering the active ingredient;
Patents covering the patch formulation;
Method-of-use patents;
Patents listed by the NDA holder after approval; and
Whether US 9,668,981 is listed for the specific NDA.

A patent number alone does not establish Orange Book listing. FDA listing must be confirmed through the current Approved Drug Products with Therapeutic Equivalence Evaluations database and the NDA-specific patent listing record. [2]

What Paragraph IV challenges and generic entry risks exist?

A generic applicant seeking approval for a transdermal methylphenidate product could address this patent through a Paragraph IV certification if the patent is listed against the relevant reference product and remains unexpired.

The principal design-around and invalidity positions would be:

Risk theory	Potential position
Noninfringement	Accused acrylic polymer contains methacrylic acid
Noninfringement	Soft or hard monomer falls outside the claimed Tg range
Noninfringement	Soft/hard monomer percentages fall outside the claimed ranges
Noninfringement	Drug loading is outside the claimed range
Noninfringement	Product uses a non-acrylic adhesive system
Noninfringement	Product does not practice the claimed transdermal administration method
Invalidity	Earlier acrylic adhesive references disclose the same monomer classes and drug loading
Invalidity	Tg ranges and composition ranges are routine optimization
Invalidity	“About” ranges lack sufficiently definite boundaries
Invalidity	Negative limitation lacks adequate written-description support
Invalidity	Broad genus claims are not enabled across the full scope

Because claim 1 is a method claim, an ANDA applicant may have to evaluate whether its proposed labeling induces or contributes to performance of the claimed transdermal-delivery method. The composition itself may be sold or manufactured without necessarily practicing the claimed method, but induced-infringement exposure can arise from instructions for use.

Which companies are challenging the patent?

The supplied claim text does not identify a Paragraph IV filer, district-court action, inter partes review, post-grant review, or settlement involving US 9,668,981. The patent’s litigation position therefore cannot be inferred from the patent document alone.

For commercial diligence, the relevant records are:

FDA Orange Book listing and patent-challenge history;
ANDA litigation under 21 U.S.C. § 355(j);
PACER district-court complaints;
Federal Circuit appeals;
USPTO Patent Trial and Appeal Board proceedings; and
Paragraph IV settlement disclosures under FDA and FTC reporting requirements.

No license, covenant not to sue, or settlement agreement is established by the claims supplied.

How does US 9,668,981 compare with competing patent estates?

US 9,668,981 is a platform formulation patent. It is broader in technical concept than a patent limited to one patch size, dosage strength, backing layer, or application period. Its strength depends on whether a marketed product actually uses the claimed acrylic monomer architecture.

Patent category	Typical scope	Relevance to US 9,668,981
Active-ingredient patent	Methylphenidate or another drug substance	Separate estate; generally not covered by this patent
Patch formulation patent	Adhesive, matrix, enhancer, or drug loading	Closest overlap
Method-of-use patent	Treatment of ADHD or another indication	Separate from the transdermal-delivery method
Manufacturing patent	Polymerization, coating, drying, or lamination	Potential production barrier
Device patent	Patch structure, backing, liner, or release control	May create additional blocking rights
Regulatory exclusivity	NDA, pediatric, orphan, or other FDA exclusivity	Independent of patent rights

A generic product can avoid this patent yet remain blocked by other formulation or device patents. Conversely, a product that avoids the principal Daytrana formulation claims may still infringe this patent if its adhesive composition satisfies claim 1.

What manufacturing and geographic barriers does the patent create?

The patent is a United States right. It can restrict:

Manufacturing in the United States;
Importation into the United States of a covered patch;
Sale or offer for sale in the United States; and
Use of the covered transdermal-delivery method in the United States.

It does not directly block manufacture and sale solely outside the United States. Parallel foreign patents would need separate review. The patent also does not automatically control manufacturing processes unless the resulting polymer composition falls within the claims or a separate process claim exists in the family.

The principal manufacturing diligence points are:

Monomer identity and purity.
Tg assignment and test methodology.
Polymer composition by weight.
Methacrylic acid content and polymerization records.
Drug concentration in the final adhesive composition.
Rubber or silicone polymer content.
Batch-to-batch formulation variation.
Coating and drying conditions that may alter polymer properties.

What is the overall patent strength?

The estate has moderate potential strength as a formulation platform and stronger relevance where a commercial patch uses the specifically claimed acrylic system. Claim 1 is technically detailed enough to avoid being a bare adhesive claim, but the breadth of the Tg and concentration ranges creates prior-art and enablement exposure.

Factor	Assessment
Technical specificity	Moderate to high
Breadth	Moderate
Methylphenidate relevance	High through claim 2
Design-around potential	Moderate to high
Orange Book leverage	Product- and listing-dependent
Litigation leverage	Strongest if accused product uses the claimed polymer recipe
Prior-art exposure	Meaningful for acrylic pressure-sensitive adhesives
Manufacturing detection	Moderate; formulation records and analytical testing are relevant
Geographic reach	United States only unless parallel family patents exist

Key Takeaways

US 9,668,981 covers a transdermal-delivery method using a defined soft/hard acrylic polymer blend and 0.3% to 30% drug.
Claim 2 specifically reaches methylphenidate-containing systems.
The negative limitation excluding acrylic polymers polymerized with methacrylic acid is a central design-around feature.
Claims 12 through 18 extend coverage to acrylic/rubber and acrylic/silicone blends.
The patent issued June 6, 2017 and appears to have an ordinary term extending to approximately 2029, subject to USPTO term calculations.
The patent is not, based on the claim text alone, proof of an Orange Book listing for Daytrana or another methylphenidate product.
Generic risk turns on the accused product’s monomer identity, Tg values, polymer percentages, drug loading, and methacrylic acid status.
No Paragraph IV challenge, litigation, license, or settlement is established by the information supplied.

FAQs

Does US 9,668,981 claim methylphenidate itself?

No. It claims a transdermal-delivery method using a specified acrylic polymer composition. Methylphenidate is added through dependent claim 2.

Can a patch avoid US 9,668,981 by using silicone adhesive only?

Generally, a silicone-only patch would not satisfy the requirement for at least one acrylic-based polymer. A hybrid acrylic/silicone system may implicate claims 16 through 18.

Does polyisobutylene automatically infringe the patent?

No. Polyisobutylene is relevant to claims 12 through 15, but the product must also satisfy the inherited acrylic-polymer, Tg, monomer-percentage, drug-loading, and methacrylic-acid limitations.

Is a product with 30% drug loading outside the patent?

Not necessarily. The claims use “about 30%,” and claim 5 expressly recites 0.3% to 30%. The exact boundary depends on claim construction and formulation measurement.

Does the patent block transdermal drugs other than methylphenidate?

Yes, potentially. Claim 1 is not limited to methylphenidate. It covers one or more drugs within the claimed composition and polymer limitations.

References

United States Patent and Trademark Office. (2017). U.S. Patent No. 9,668,981, transdermal drug delivery systems comprising acrylic polymer compositions.
U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations, Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/
United States Patent and Trademark Office. (n.d.). Patent Center. https://patentcenter.uspto.gov/
U.S. Food and Drug Administration. (n.d.). Abbreviated new drug application patent certifications and Paragraph IV litigation framework. https://www.fda.gov/drugs/abbreviated-new-drug-application-anda/anda-submissions-content-and-format/paragraph-iv-certifications-and-30-month-stays.

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
World Intellectual Property Organization (WIPO)	2006041911	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Details for Patent: 9,668,981

Summary for Patent: 9,668,981